Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1982 1
1984 3
1985 1
1986 3
1987 1
1988 6
1989 11
1990 15
1991 15
1992 23
1993 26
1994 25
1995 22
1996 24
1997 23
1998 20
1999 30
2000 33
2001 19
2002 34
2003 28
2004 16
2005 28
2006 39
2007 30
2008 42
2009 31
2010 56
2011 67
2012 39
2013 39
2014 44
2015 57
2016 59
2017 60
2018 51
2019 56
2020 51
2021 63
2022 74
2023 56
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

1,231 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Immunodeficiency 117"
Page 1
Mpox in people with advanced HIV infection: a global case series.
Mitjà O, Alemany A, Marks M, Lezama Mora JI, Rodríguez-Aldama JC, Torres Silva MS, Corral Herrera EA, Crabtree-Ramirez B, Blanco JL, Girometti N, Mazzotta V, Hazra A, Silva M, Montenegro-Idrogo JJ, Gebo K, Ghosn J, Peña Vázquez MF, Matos Prado E, Unigwe U, Villar-García J, Wald-Dickler N, Zucker J, Paredes R, Calmy A, Waters L, Galvan-Casas C, Walmsley S, Orkin CM; SHARE-NET writing group. Mitjà O, et al. Lancet. 2023 Mar 18;401(10380):939-949. doi: 10.1016/S0140-6736(23)00273-8. Epub 2023 Feb 21. Lancet. 2023. PMID: 36828001
At mpox diagnosis, 349 (91%) individuals were known to be living with HIV; 228 (65%) of 349 adherent to antiretroviral therapy (ART); 32 (8%) of 382 had a concurrent opportunistic illness. The median CD4 cell count was 211 (IQR 117-291) cells per mm(3), with 85 (22%) indiv …
At mpox diagnosis, 349 (91%) individuals were known to be living with HIV; 228 (65%) of 349 adherent to antiretroviral therapy (ART); 32 (8% …
Central nervous system infection with Toxoplasma gondii.
Marra CM. Marra CM. Handb Clin Neurol. 2018;152:117-122. doi: 10.1016/B978-0-444-63849-6.00009-8. Handb Clin Neurol. 2018. PMID: 29604970 Review.
Central nervous system infection by Toxoplasma gondii, or Toxoplasma encephalitis, is the most common cause of brain mass lesions in human immunodeficiency virus (HIV)-infected patients. It usually presents as one or more brain abscesses, but it can also cause a diffuse en …
Central nervous system infection by Toxoplasma gondii, or Toxoplasma encephalitis, is the most common cause of brain mass lesions in human …
AIDS and COVID-19 in southern Africa.
van Wyngaard A, Whiteside A. van Wyngaard A, et al. Afr J AIDS Res. 2021 Jul;20(2):117-124. doi: 10.2989/16085906.2021.1948877. Afr J AIDS Res. 2021. PMID: 34264162
Syndromic immunodeficiencies: a pediatrician's perspective on selected diseases.
Szczawinska-Poplonyk A, Begier K, Dorota A, Dabrowska M, Galecka D, Wawrzeniak K, Wroblewski K. Szczawinska-Poplonyk A, et al. Allergol Immunopathol (Madr). 2021 Jul 1;49(4):117-136. doi: 10.15586/aei.v49i4.200. eCollection 2021. Allergol Immunopathol (Madr). 2021. PMID: 34224226 Review.
BACKGROUND: Syndromic immunodeficiencies are a genetically and pathophysiologically heterogeneous group of inborn errors of immunity. ...OBJECTIVE: To increase the pediatricians' awareness of this multifaceted group of primary immunodeficiencies in children. METHODS …
BACKGROUND: Syndromic immunodeficiencies are a genetically and pathophysiologically heterogeneous group of inborn errors of immunity. …
Defects of class-switch recombination.
Notarangelo LD, Lanzi G, Peron S, Durandy A. Notarangelo LD, et al. J Allergy Clin Immunol. 2006 Apr;117(4):855-64. doi: 10.1016/j.jaci.2006.01.043. J Allergy Clin Immunol. 2006. PMID: 16630945 Review.
However, the molecular mechanisms underlying these important processes have long remained obscure. Immunodeficiency with hyper-IgM comprises a group of genetically heterogeneous defects of CSR variably associated with defects of SHM. ...
However, the molecular mechanisms underlying these important processes have long remained obscure. Immunodeficiency with hyper-IgM co …
Immunodeficiency, AIDS-related pneumonia, and risk of lung cancer among HIV-infected individuals.
Marcus JL, Leyden WA, Chao CR, Horberg MA, Klein DB, Quesenberry CP Jr, Towner WJ, Silverberg MJ. Marcus JL, et al. AIDS. 2017 Apr 24;31(7):989-993. doi: 10.1097/QAD.0000000000001434. AIDS. 2017. PMID: 28252529 Free PMC article.
OBJECTIVE: The objective is to clarify the role of immunodeficiency and pneumonia in elevated lung cancer risk among HIV-infected individuals. ...CONCLUSION: The increased lung cancer risk among HIV patients is attributable to differences in demographics, risk factors such …
OBJECTIVE: The objective is to clarify the role of immunodeficiency and pneumonia in elevated lung cancer risk among HIV-infected ind …
HIV in pregnancy.
Moodley J, Wennberg JL. Moodley J, et al. Curr Opin Obstet Gynecol. 2005 Apr;17(2):117-21. doi: 10.1097/01.gco.0000162178.38231.1d. Curr Opin Obstet Gynecol. 2005. PMID: 15758601 Review.
PURPOSE OF REVIEW: This review discusses recent articles on various aspects of the prevention of mother-to-child transmission during pregnancy and delivery. RECENT FINDINGS: Rapid human immunodeficiency virus (HIV) testing of women in labour whose status is not known allow …
PURPOSE OF REVIEW: This review discusses recent articles on various aspects of the prevention of mother-to-child transmission during pregnan …
Spectrum and Incidence Trends of AIDS- and Non-AIDS-Defining Cancers between 2010 and 2015 in the French Dat'AIDS Cohort.
Poizot-Martin I, Lions C, Allavena C, Huleux T, Bani-Sadr F, Cheret A, Rey D, Duvivier C, Jacomet C, Ferry T, Cabie A, Fresard A, Pugliese P, Delobel P, Lamaury I, Chirouze C, Zaegel-Faucher O, Brégigeon S, Rojas Rojas T, Obry-Roguet V, Makinson A. Poizot-Martin I, et al. Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):554-563. doi: 10.1158/1055-9965.EPI-20-1045. Epub 2020 Dec 11. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 33310788 Free article.
Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease.
Kriván G, Borte M, Harris JB, Lumry WR, Aigner S, Lentze S, Staiger C. Kriván G, et al. Vox Sang. 2022 Oct;117(10):1153-1162. doi: 10.1111/vox.13337. Epub 2022 Aug 9. Vox Sang. 2022. PMID: 35944615 Clinical Trial.
BACKGROUND AND OBJECTIVES: To evaluate the efficacy, safety and pharmacokinetics of a new, highly purified 10% IVIg (BT595, Yimmugo) administered in children and adults with Primary immunodeficiency diseases (PID). MATERIALS AND METHODS: Prospective, uncontrolled, multicen …
BACKGROUND AND OBJECTIVES: To evaluate the efficacy, safety and pharmacokinetics of a new, highly purified 10% IVIg (BT595, Yimmugo) adminis …
1,231 results